Table 2.
Rate of change of clinical parameters of GCC after 3 and 7 weeks of treatment with ATR or FOE (%)
| 3 weeks Assessment |
7 weeks Assessment |
|||
|---|---|---|---|---|
| FOE | ATR | FOE | ATR | |
| RCKPS | 0.33–0.47 | 0.47–0.73*P1 | 0.60–1.00 | 0.93–1.47*P2 |
| RCA | 1.16–1.43 | 2.09–2.11*P3 | 2.13–2.27 | 2.46–2.73*P4 |
| RBWL | 0.02–0.04 | 0.01–0.03 | −0.02–0.00 | −0.01–0.01 |
| RCMAMC | 0.02–0.04 | 0.03–0.05 | 0.10–0.12 | 0.07–0.11 |
GCC: Gastric cancer cachexia; ATR: Atractylenolide I; FOE: Fish-oil-enriched nutritional supplementation group; RCKPS: rate of change of KPS status; RCA: rate of change of appetite scale; RBWL; rate of body weight loss; RCMAMC: rate of change of mid-arm muscle circumference. *P < 0.05 vs. fish-oil-enriched nutritional supplementation group. *P1 = 0.01; *P2 = 0.02; *P3 = 0.00; *P4 = 0.00.